ClinicalTrials.gg
CompletedNCT02269319ABSSSIUpdated Nov 4, 2024Results posted

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

A Phase 2 interventional study of MRX-I and Linezolid in Bacterial Infections, sponsored by MicuRx. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by MicuRx · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

02

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • ABSSSI
  • MRX-I
  • Acute Bacterial Skin and Skin Structure Infections
03

In context

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

This study's enrollment of 120 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI)
  • Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

Exclusion criteria

Exclusion Criteria:

  • Uncomplicated skin infections
  • Severe sepsis or septic shock
  • ABSSSI solely due to gram-negative pathogens
  • Prior systemic antibiotics within 96 hours of randomization
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    MRX-I

    MRX-I tablets 800 mg given twice a day for 10 days

    Drug: MRX-I

  • Active comparator
    Linezolid

    Linezolid 600 mg given twice a day for 10 days

    Drug: Linezolid

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline

    * Did not receive a systemic antibacterial agent with activity against gram-positive organisms * Did not die of any cause up to EA

    Time frame: 48-72 hours

Secondary outcomes

  1. Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline

    Time frame: Day 10

07

Results

Posted Nov 4, 2024
Limitations and caveats
Proof of concept study was limited in size and scope. Given the number of male to female subjects, the interpretation of the results were limited. Since the duration of therapy was up to 10 days, assessment of long-term safety risks was limited.

Participant flow

Participant flow — Overall Study
MilestoneMRX-ILinezolid
Started8040
Completed7536
Not completed54
Withdrew: Lost to follow-up43
Withdrew: Adverse event01
Withdrew: Instructions not followed10

Outcome measures

PrimaryNumber of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline

* Did not receive a systemic antibacterial agent with activity against gram-positive organisms * Did not die of any cause up to EA

Time frame:
48-72 hours
Reported as:
Count of participants · Participants
Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline
ParticipantsMRX-ILinezolid
Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline7235
SecondaryNumber of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline
Time frame:
Day 10
Reported as:
Count of participants · Participants
Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline
ParticipantsMRX-ILinezolid
Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline7032

Adverse events

Collected over 39 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MRX-I0/80 (0%)1/80 (1.3%)47/80 (58.8%)
Linezolid0/40 (0%)0/40 (0%)12/40 (30%)
Most frequent serious events
Most frequent serious events
EventMRX-ILinezolid
NephrolithiasisRenal and urinary disorders1/800/40
Most frequent other events
Most frequent other events
EventMRX-ILinezolid
NauseaGastrointestinal disorders12/804/40
AbscessInfections and infestations9/803/40
VomitingGastrointestinal disorders7/803/40
CellulitisSkin and subcutaneous tissue disorders5/801/40
Urinary Tract InfectionInfections and infestations5/800/40
HypertensionVascular disorders3/801/40
HeadacheNervous system disorders3/800/40
Upper Respiratory Tract InfectionsInfections and infestations3/800/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)MRX-ILinezolidTotal
Mean37.9 (20 to 62)38.8 (22 to 61)38.2 (20 to 62)
Sex: Female, Male
Sex: Female, Male(Participants)MRX-ILinezolidTotal
Female271340
Male532780
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2024, 9 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2014
First posted
Oct 21, 2014
Start
Feb 2015
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Results first posted
Nov 4, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02269319
Lead sponsor
MicuRx
Responsible party
Sponsor
First posted
Oct 21, 2014
Start date
Feb 2015
Primary completion
Aug 2015
Completion
Sep 2015
Results posted
Nov 4, 2024
Last update
Nov 4, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Contezolid

Start the discussion